Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc. (ERNAW) is a US-listed equity tracked across major market indices. Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

The company reports trailing twelve-month revenue of $582,000 and net loss of $5.51M. Key metrics include a return on equity of -80.3%, a debt-to-equity ratio of 0.54.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for ERNAW to support both active traders and long-term investors.